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The majority of patients with metastatic germ cell tumors can be cured with currently available poly-chemotherapy. Based on presenting criteria three prognostic groups can be dis cerned. In patients with a good prognosis (> 90% probability of 5-year survival) attempts have been made to diminish the dose of the active compounds in the B E P regimen. The omission of bleomycin cannot be recommended on pres ently available data; and a total dose of at least 240 mg seems appropriate. Platinum at a dose intensity below 75 mg/m2/ 3 weeks compromised efficacy and the recommended dose is 100 mg/m2. A true comparison between the two most frequently used etoposide doses has not been performed. Based on the available literature etoposide should be given In doses of at least 360 mg/m2/cycle when four courses are given and 500 mg/m2/cycle when three courses are given. For intermediate and high-risk patients alternating, acceler ated and high-dose chemotherapy can be considered. None of the alternating and accelerated regimens has a proven advantage in randomized trials and they remain investiga tional. The addition of hematopoietic growth factors permits a higher dose intensity of BEP/EP and BOP/VIP; although to date there is no proven impact on outcome. The application of high-dose chemotherapy for one to four courses Is feasi ble with the support of both hematopoietic growth factors and autologous bone marrow or peripheral stem cells. In true chemotherapy-resistant disease the value of this approach seems limited. Its role In patients with a first relapse should be further explored. The approach of high-dose chemother apy in first line for patients with poor prognostic features should preferentially be investigated In a randomized fash ion, but this will require extensive international collabora tion in view of the low incidence and the expected advantage of the approach.
Since the introduction of cisplatin CP) 1 major progress has been m ade, the m ajority of patients now obtain ing cure ev en w ith far advanced m etastatic disease, At the m om ent several active drugs are identified for this disease: cisplatin, bleom ycin, vinblastine, etoposide, ifosfam ide, carboplatin, cy clo p h o sp h a mide; to a lesser extent adriam ycin and actinomycin-d; and m ore recently paclitaxel. 2 The first breakthrough cam e from the com bination of cis platin, vinblastine (0.4 m g/kg) and bleom ycin given q 3 w eeks x 4 follow ed by 21 m onths vinblastine m aintenance therapy, From this early experience it also becam e clear that additional courses after four courses of PVB (cisplatin, vinblastine, bleom ycin) w ere clinically not inducing m ore com plete rem is sio n s.3 This indicated that a higher total dose of these drugs did not contribute and the standard num ber w as established to be four, The total dose of vinblastine in this study was high and contributed significantly to the o b serv ed toxicity. In a su b se q u en t study the higher dose of vinblastine (0.4 vs 0.3 m g/kg) resulted in sim ilar therapeutic efficacy. '1 The n um ber of patients treated in this study (26 vs 27) was low and therefore does not m eet the stat istical criteria for equivalence in outcom e. It result ed, how ever, in the establishm ent of the reduced vinblastine dose as the standard, In an o th er ran dom ized study om ission of the m aintenance treat m ent with vinblastine w as also show n not to com prom ise o u tc o m e .1 ' T hese studies w ere am ong the first to look at dose intensity and total dose given in relation to treatm en t o u tco m e. T he su b seq u en t discovery of eto p o sid e as an active agent with a different toxicity profile led to the developm ent of the BEP (bleom ycin, eto p o sid e, cisplatin) com bina tion and this is the b a c k b o n e of p resen t chem other apy for m etastatic germ cell tu m o rs/1 "" This therapy results in the cure of approxim ately 70%-H0% of patients. Factors associated with treatm ent failure have been analyzed in several large studies and PHM De Mulder a n d R de Wit in clu d e large tu m o r volum e, the presence of liver, tients w ere characterized by lym ph n o d es < 5 cm, b o n e or b rain m étastasés, grossly elevated tum or lung m etastasis < 2 cm, a Ipha-foe to protein (AFP) < 1000 ng/m l, hum an chorionic gonadotrofin (HCG) < 10,000 IU/1. T oday th e cut-off values for the m arkers, and an e x trag o n ad al prim ary site, particu larly in the m e d ia stin u m .y~15 B ased on these p ro g nostic factors clinical trials have investigated either m arkers are still valid, but m ore recent prognostic d e c re a sin g d o ses to dim inish the toxicity of the factor analyses have sh o w n that patients w ith m ore sta n d a rd of four BEP cycles in patients w ith good-extensive m étastasés can still be categorized as risk d isease (p re d ic te d cu re rate > 90%), or im prov-having a g o o d prognosis. W ith 393 patients entered ing the results by intensifying therapy in patients into the study, 97% of the evaluable patients receivw ith in term ed iate-risk (p red icted cure rate 80%) ing BEP and 91% of patients receiving EP achieved a n d p o o r-risk (p re d ic te d cure rate 50%) disease.
com plete rem ission, O f the com plete responders, Studies of d o se a n d re sp o n se in germ cell tu-6 receiving EP and 7 receiving BEP relapsed. Alm ours are n o t ex ten siv e and provide only limited though there w as no statistical difference b etw een e v id e n c e to s u p p o r t th e d o s e -re s p o n s e m odel, the two arms a few m ore patients p ro g ressed and died on the EP arm, ev en th o u g h the eligibility criteria actually selected for ultra-good, prognostic S ch ed u le d e p e n d e n c y is quite often ignored in this context, as is sy n erg y b e tw e e n d ru g s. 16 In studies ap p ly in g altern atin g th erap eu tic agents it is im por-patients. The n u m b er of events in this study is low tan t that active c o m p o u n d s w ith a different m e d ia -and the study therefore lacks the p o w e r to give a nism of actio n are used, It is against this b ack g ro u n d final answ er. At the sam e tim e an ECOG prospective that the p re se n tly available literature sh o u ld be assessed.
Chemotherapy in good-risk disease
random ized study com paring three courses of BEP (etoposide 500 m g /m 2/cycle) w ith three courses of EP in patients w ith m inim al or interm ediate disease by the Indiana classification sh o w ed progressionfree survival of only 69% in the patients using the tw o-drug schedule co m p ared to 85% w ith three As m e n tio n e d ab o v e , clinical trials in patients w ith drugs.18 It is im portant to realize that the Indiana a high p ro b ab ility o f cu re have focused o n decreas-goocl-prognosis group also com prises patients of ing the toxicity of sta n d a rd c h e m o th e ra p y .2,17 At the interm ediate g ro u p according to the EORTC p resen t a 5-day reg im en of BEP is co n sid ered the classification. It is obvious that bleom ycin can n o t be "gold s ta n d a rd ", usu ally adm Bleomycin vestigatecl w hether, in those with good-prognosis NSGCC, three courses of BEP was equivalent to the standard four-courses re g im e n .19 T he trial w as d e signed to show a < 10% difference in the response rate for three courses co m p ared with four courses. O ne h u n d red and eighty-four patients en tered the study. Eighty-six of 88 patients (98%) random ized 
Germ cell tumors
It has since b een q u estio n ed w h e th e r this trial In a series of 127 patients [Vom the MRC with metaof only ' 184 patients had provided sufficient data to conclude that three BEP equals four BEP as far as static germ cell cancer w ho had b e e n treated with four BEP cycles consisting of cisplatin 20 m g /m 2 progression-free survival and survival are concerned.
per day on days 1-5 , eto p o sid e 120 m g /m 2 per day A lthough the sam ple size w as sufficient to detect a 10% difference at a p o w er of 85%, it did not allow on days 1-3, a n d bleom ycin 30 mg on days 2 , 9 and 16, a w hite cell count nadir of < 1.0 x 10'7 1 occurred the d etectio n of a clinically m eaningful difference in only 2% o f 482 c o u rs e s .7 T h ere w ere three b etw een 5% a n d 9%. Of equal im p o rtan ce w as that episodes of n eu tro p en ic sepsis, with one death in the m edian follow -up of 19 m onths is probably not a patient w ho had received additional high-dose sufficient to m ake the result of this stu d y definitive.
m ethotrexate for poorly resp o n d in g bulky disease. There has b een no form al u p d ate since (personal Significant th ro m b o cy to p en ia w as rarely seen and com m unication, P. Loehrer, study coordinator, 16 platelet counts < 50,000 x 10'Yl occurred in 2% of May 1994), In E urope three cycles are therefore not generally accep ted as the standard treatm ent. In a disease w h ere cure can be achieved in over 90% 482 courses. E ighteen patients h ad treatm ent delays of m ore than 2 w eeks b etw een the start of chem o therapy and the e x p e c te d date of com pletion of the of patients a difference of 5%-9% is n o t acceptable fourth course of therapy. D elays occurred predomand it is generally agreed that a n e w trial should be carried out to rule out a > 5% difference in progression-free survival, w ith sufficient follow -up, In March 1995 the MRC and EORTC em b ark ed on a inanl'ly in the earlier part of the series (1979) (1980) (1981) (1982) (1983) w h en ch em o th erap y w as w ithheld w ith total w hite cell counts < 2.5 x lOVL The investigators reported that there w as no relationship b etw een these short large random ized trial that is designed as an equiv-treatm ent delays and stage of disease and no effect alence study com paring four vs three cycles of BEP on recurrence or survival w as apparent; the actual'in m ore than 700 patients, w hich en ab les exclusion ial 5-year recu rren ce-free survival w as 79% for of a small but m eaningful difference.
Etoposide dose
Finally, the dose of eto p o sid e in the BEP regim en rem ains subject to discussion. W hereas investiga tors in E urope have u sed eto p o sid e 120 m g /m 2, days 1, 2, 3 (MRC) or 1, 3, 5 (EORTC), in the US 100 m g /m r per day, days 1-5 has alw ays been the preferred schedule. No studies have ad d ressed the issue of the optim al dose of eto p o sid e p e r cycle in a com parative fashion.
Cisplatin vs carboplatin
no delay co m p ared to 85% for delay > 1 w eek. It should be em p h asized that the n u m b er of patients at risk was low (18) a n d therefore this observation, though reassuring, does not constitute scientific proof.
W hen a 5-day sch ed u le of eto p o sid e 100 m g /m 2 per day is used, the incidence of grade 3/4 leukocytopenia and n eu tro p en ia is m ore frequent, res ulting in a w hite cell nadir < 1.0 x 10*71 in 20% and incidence of fever during n eu tro p en ia in 15% of patients at som e time during treatm ent. In a series of 123 patients treated at Indiana University over 50%i of patients had an absolute neutrophil count < 0.5 x KV71 at som e time during treatm en t. 22 Tw o The role of carboplatin as rep lacem en t for cisplatin patients died of sepsis w hile they had neutropenia, is b ey o n d the scope of this review and will therefore not be discussed in detail. Based on th e available data cisplatin should be the drug of c h o ic e .20,21
Fourteen p e r cent of patients had a platelet count <50,000 x 10VI at som e time during treatm ent. In the previously-m entioned study of 184 patients w ho received either three or four BEP cycles, one patient died from chem o th erap y -related sep sis. 19 As it apco n sid ered the gold stan d ard c h e m o th e ra p y in pears from this latter study that the efficacy of three And-On i cer I)r t i#s • 1 \ > 1 6, Si (ppl 5 • / 99 45 goocl-risk p atien ts tre a te d w ith either VAB-6 (vin-Drug com binations in seq u en ce have b een exblastine, b leo m y cin , actinom ycin-D , cyclophospha-plored at the Charing Cross H ospital w ith POM1V micle, cisplatin) at 28-day intervals for three cycles ACE chem o th erap y (cisplatin, vincristine, metlioor four cycles o f EP at 21-day intervals.2* T reatm ent trexate, bleom ycin/actinom ycin-D , cyclophosphaw as routinely p o s tp o n e d for 7 days for leukocytes micle, etoposide). Recently, an u p d a te d analysis < 3*0 x 109/1 or p latelets < 100 x 109/1 on th e day of w as published con cern in g 206 patients treated bep la n n e d tre a tm e n t a n d th e ra p y w as then ad min is-tw een 1977 a n d 1988. 26 In a further study 106 out tered reg There w ere a total of 14 deaths attributed to toxicity, 6 on BEP and 8 on BOP/VIP. This prelim inary analysis sug gests no advantage to the alternating and more intensive schedule, although longer follow-up is required. In a subgroup of 263 patients, a second random ization w as perform ed in order to investi gate w h e th e r the scheduled dose or either BOP/VIP or BEP/EP could be better m aintained with the addition of granulocyte-colony stimulating factor (G-CSF). A p relim in ary analysis in d icated that 10% better dose ad h eren ce w as achieved with the addition of G-CSF, but that the better dose adher ence did not result in a significant im provem ent of progression-free survival (69% vs 68%) or overall survival (76% vs 80%), no G-CSF vs plus G-CSF res pectively.33 The m ain explanation for a lack of benefit from these chem o th erap y com binations may be that cis platin resistance is the crucial factor for treatm ent failure in testicular cancer, and that alternating vin blastine an d etoposide or etoposide and ifosfamide will not have a substantial im pact on the efficacy of these com bin atio n s.34 Agents w ith m ore im portant activity in refractory disease such as the taxanes are alternative candidates for drug com binations which m ay m erit further testing of alternating chem o th e ra p y .2 A lthough treatm ent w ith BEP remains the gold-standard therapy, random ized com parative trials with other schedules, given in either an alter nating or a sequential fashion, w ith or w ithout an intensive induction phase, are justified.
Intermediate-and poor-prognosis disease

increased dose per cycle
The rationale for the use of dose-intensified chem o therapy in intermediate-and poor-risk patients is based on preclinical evidence of a dose-response relationship. Because of dramatically im proved res ponse rates and survival with the introduction of cisplatin into combination chem otherapy regimens, escalation of cisplatin dose was one of the first attempts m ade to further improve clinical results.
The South Western Oncology Group (SWOG) conducted a random ized study with PVB at a cis platin dose of either 120 m g/m 2 every 4 w eeks or cisplatin 75 m g/m 2 every 4 w eek s. 35 There was a significant increase in the complete response rate and survival for patients in the cisplatin 120 m g/m 2 arm. The clinical meaning of cisplatin dose intensity in this trial was ham pered by the relatively low dose intensity of cisplatin in the 75 m g/m 2 arm of 0.58 com pared to standard BEP. The relevance of this study is that it underlines the im portance of m ain taining the standard cisplatin dose intensity an d that reduction to 75 m g/m 2 has a detrim ental effect on treatm ent outcome.
The apparent improvement of increased-dose cisplatin was accentuated by a study perform ed by the National Cancer Institute (NCI) that w as d e signed to determine w hether superior results could be obtained by maximum doses of chem otherapy comprising cisplatin 200 m g/m 2, etoposide 500 m g/ m 2, vinblastine 0.2 mg/kg per cycle every 3 w eeks, and bleomycin 30 mg weekly, relative to a standard schem e of PVB, i.e. cisplatin 100 m g /m 2, vinblastine 0.3 m g/kg every 3 weeks and bleom ycin 30 mg w eekly. 36 Of the patients random ized to the highdose arm, 88% obtained disease-free status com pared to 67% in the standard arm. This study has frequently been cited to advocate the im portance of cisplatin dose intensity in poor-risk germ cell can cer, but the results should be interpreted cautiously since the addition of full-dose etoposide w as the other variable in the high-dose cisplatin regimen.
These studies were accom panied or follow ed by a num ber of phase II trials that invariably reported superior outcom e but as m entioned earlier are dif ficult to interpret since a myriad of classification systems to assign poor risk w ere a p p lie d . 27, 28, 37 Trials have included patients that by other classifi cation systems w ould be regarded as good-risk, 
